Danish biotech firm LifeCycle Pharma has entered strategic collaboration agreements with global pharmaceutical companies Sandoz Inc and Merck Generics. Sandoz Inc, an affiliate of Novartis AG, and LifeCycle Pharma have entered an exclusive development and commercialisation agreement for the US market regarding an undisclosed fenofibrate* product developed by LifeCycle Pharma. In 2005, the US market for fenofibrate products exceeded USD 1 bn.
Merk Generics, a subsidiary of Merck KGaA, and LifeCycle Pharma have entered an exclusive development and commercialisation agreement for the European market concerning a fenofibrate product. In 2005, the European market for fenofibrate products was approx. USD 235 m.
LifeCycle Pharma's pipeline contains five products in clinical trials, of which the first, LCP-FenoChol, a cholesterol lowering compound, is expected to reach the market early in 2008. Michael Wolff Jensen, finance director of LifeCycle Pharma says: "We will soon be filing a registration application in the US for LCP-FenoChol. It has not yet been decided whether we should also have a partner for this product."
LifeCycle Pharma is based in Hørsholm north of Copenhagen. The company utilizes its proprietary Meltdose technology to improve the bioavailability of known and established compounds so that patients can absorb them more effectively. The news was reported by financial daily newspaper Børsen
*fenofibrates are used to help lower triglyceride and cholesterol levels – Ed.
Link > LifeCycle Pharma